Rapport Therapeutics completes $410.7 million capital raise

Rapport Therapeutics announced the closing of its underwritten public offerings of common stock, pre‑funded warrants and 2.25% convertible senior notes due 2032. The company sold 9,761,905 shares of common stock at $21.00 per share, exercised the underwriters’ option for an additional 1,428,571 shares, issued pre‑funded warrants for up to 1,190,476 shares at $20.999 each, and raised $172.5 million of notes, plus a concurrent private placement of 1,428,571 shares. Net proceeds are estimated at approximately $410.7 million.

The company said the proceeds will fund ongoing and planned RAP‑219 clinical trials and support operations through the end of 2029. The large equity and note issuance is highly dilutive, which has already pressured the share price.

  • 1Rapport sold 9,761,905 shares of common stock at $21.00 per share.
  • 2The underwriters exercised their option to purchase an additional 1,428,571 shares of common stock.
  • 3Pre‑funded warrants were issued for up to 1,190,476 shares at $20.999 per warrant.
  • 4The offering included $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032.
  • 5A concurrent private placement sold 1,428,571 shares at the $21.00 offering price.
  • 6Aggregate net proceeds are approximately $410.7 million after expenses.

Sources